311 filings
Page 6 of 16
CORRESP
hmx3ptb
11 Feb 19
Correspondence with SEC
12:00am
4
0z7l1xj fbgk6d
8 Feb 19
Aeglea BioTherapeutics / Anthony G. Quinn ownership change
4:15pm
SC 13G
oovlac
8 Feb 19
Aeglea BioTherapeutics, Inc.
12:00am
8-K
b05fzlj7r w9w98ij2g4
6 Feb 19
Entry into a Material Definitive Agreement
9:40pm
424B5
6t630aed
6 Feb 19
Prospectus supplement for primary offering
9:37pm
424B5
tp52zs tmgg
5 Feb 19
Prospectus supplement for primary offering
4:49pm
SC 13G/A
4edau hpt
5 Feb 19
Aeglea BioTherapeutics, Inc.
4:06pm
UPLOAD
lrt2gizx5udab3k
4 Feb 19
Letter from SEC
12:00am
SC 13G/A
iq8mbgs ze73xvp1w3
31 Jan 19
Aeglea BioTherapeutics, Inc.
4:37pm
SC 13G/A
jba4ey473uxm6hr8cxq
31 Jan 19
Aeglea BioTherapeutics, Inc.
11:20am
8-K
5vjt8i f5h1
21 Dec 18
Termination of a Material Definitive Agreement
4:01pm
8-K
izv3szgk5aucwpi8jn
11 Dec 18
Regulation FD Disclosure
5:05pm
8-K
ss6cw78z
11 Dec 18
Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency
4:05pm
4
aiiy7 6zny16vrc83
10 Dec 18
Aeglea BioTherapeutics / Anthony G. Quinn ownership change
5:40pm
8-K
2gyhy3n
29 Nov 18
Entry into a Material Definitive Agreement
8:00am
8-K
f2ivk9s u38y
8 Nov 18
Aeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
8:00am
8-K
e8zu6xe
22 Oct 18
Regulation FD Disclosure
8:00am